Hims & Hers cuts 2026 profit forecast as margins contract
HIMS•Hims & Hers cut its 2026 core earnings forecast to $257 million to $277 million from $275 million to $325 million. Quarterly revenue rose 49% to $890.4 million, while gross margin fell to 57% from 74% a year earlier.
1. Forecast reduced
Hims & Hers Health cut its full-year 2026 core earnings forecast as higher costs tied to branded weight-loss drugs and international expansion pressured margins. The company now expects core earnings of $257 million to $277 million, down from its previous forecast of $275 million to $325 million.
2. Quarterly results
Quarterly revenue rose 49% to $890.4 million, slightly below analysts’ average estimate of $892.9 million. The company posted a net loss of $33 million, compared with net income of $15.8 million a year earlier. Gross margin fell to 57% from 74%.
3. Subscriber growth
Hims’ subscriber base grew 13% to nearly 2.8 million, and monthly revenue per average subscriber increased 30% to $105. U.S. revenue rose 21% to $657.1 million, while international revenue more than quadrupled to $233.3 million.
